日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

出版商更正:HER2相关生物标志物可预测HER2表达转移性结直肠癌患者接受曲妥珠单抗德鲁替康治疗的临床结果:DESTINY-CRC01研究的生物标志物分析

Siena, Salvatore; Raghav, Kanwal; Masuishi, Toshiki; Yamaguchi, Kensei; Nishina, Tomohiro; Elez, Elena; Rodriguez, Javier; Chau, Ian; Di Bartolomeo, Maria; Kawakami, Hisato; Suto, Fumitaka; Koga, Makito; Inaki, Koichiro; Kuwahara, Yusuke; Takehara, Issey; Barrios, Daniel; Kobayashi, Kojiro; Grothey, Axel; Yoshino, Takayuki

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

HER2相关生物标志物可预测HER2表达转移性结直肠癌患者接受曲妥珠单抗德鲁替康治疗的临床结果:DESTINY-CRC01研究的生物标志物分析

Siena, Salvatore; Raghav, Kanwal; Masuishi, Toshiki; Yamaguchi, Kensei; Nishina, Tomohiro; Elez, Elena; Rodriguez, Javier; Chau, Ian; Di Bartolomeo, Maria; Kawakami, Hisato; Suto, Fumitaka; Koga, Makito; Inaki, Koichiro; Kuwahara, Yusuke; Takehara, Issey; Barrios, Daniel; Kobayashi, Kojiro; Grothey, Axel; Yoshino, Takayuki

Secreted Ephrin Receptor A7 Promotes Somatic Cell Reprogramming by Inducing ERK Activity Reduction.

分泌型 Ephrin 受体 A7 通过诱导 ERK 活性降低来促进体细胞重编程

Lee Joonseong, Nakajima-Koyama May, Sone Masamitsu, Koga Makito, Ebisuya Miki, Yamamoto Takuya, Nishida Eisuke